Basic Information
| LncRNA/CircRNA Name | circBA9.3 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Tyrosine kinase inhibitors | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | chronic lymphocytic leukemia |
| ICD-0-3 | NA |
| Methods | 3D-dPCR, qRT-PCR, Flow cytometry analyses of apoptotic cells, Western blots |
| Sample | Peripheral blood samples, CML tissues, cell lines K562 and Ku812, 293 T/17 |
| Expression Pattern | up-regulated |
| Function Description | CircBA9.3 can efficiently promote the proliferation and inhibit apoptosis of cancer cells. In addition, some patients with TKI resistance have elevated circBA9.3 expression, which is positively correlated with the level of BCR-ABL1. Furthermore, circBA9.3 is predominantly located in the cytoplasm and enhances cABL1 and BCR-ABL1 oncoprotein expression. Thus, circBA9.3 is a molecule associated with increased tyrosine kinase activity that promotes resistance against TKI therapy. In this study, we provided a new potential target for the treatment of TKI-resistant CML patients. |
| Pubmed ID | 30224298 |
| Year | 2018 |
| Title | CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels |
External Links
| Links for circBA9.3 | GenBank HGNC NONCODE |
| Links for chronic lymphocytic leukemia | OMIM COSMIC |